Search results
Results from the WOW.Com Content Network
Image source: Getty Images. Bristol Myers Squibb (NYSE: BMY), or BMS for short, is a prime example.The drugmaker's shares are down by over 17% year to date and over 33% over the prior 12 months.
(Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older ...
It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following the loss of patent exclusivity of two important medicines in its ...
Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey , [ 2 ] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading on Friday. Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of ...